NEW MJ NEWS

Sundial Growers Inc to Host Earnings Call

Sundial Growers Inc (NASDAQ:SNDL) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 12, 2020 at 10:30 AM Eastern Time.

To listen to the event live or access a replay of the call – visit
https://www.investornetwork.com/event/presentation/70999

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company’s profile.

– ADVERTISEMENT –

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

View source version on accesswire.com:
https://www.accesswire.com/616219/Sundial-Growers-Inc-to-Host-Earnings-Call


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Verano Holdings Corp. (VRNOF) Announces First Quarter 2024 Financial Results

Verano Announces First Quarter 2024 Financial Results Verano Holdings Corp. (Cboe CA:…

Cresco Labs (CRLBF) Opens Second Pensacola Florida Dispensary

Cresco Labs Opens Second Pensacola Florida Dispensary Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco”…

HEXO (HEXO) to participate in the A.G.P.’s Virtual Fall Consumer Cannabis Conference

HEXO to participate in the A.G.P.’s Virtual Fall Consumer Cannabis Conference HEXO…

Tetra Bio-Pharma (TBPMF) Discusses FDA Orphan Drug Designation for Its Ophthalmic Program and Cannabinoid-Based Topical Cream

Tetra Bio-Pharma Discusses FDA Orphan Drug Designation for Its Ophthalmic Program and…